Testing AZD6234 for Adults With Type 2 Diabetes and Excess Weight
Tests AZD6234 against placebo in adults with type 2 diabetes and excess weight.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Key facts
- Where
- Buenos Aires, CABA, Ciudad de Buenos Aires, Mendoza, Ramos Mejía, Rosario, and San Nicolás, ArgentinaSee the 7 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who also have overweight or obesity. It compares AZD6234 with placebo for weight change over 68 weeks.
- Age
- 18 years or older
- Sex
- All sexes and gender identities can join.
- Disease stage
- Type 2 diabetes diagnosed at least 90 days before screening, with BMI of 27 kg/m2 or more and HbA1c between 6.0% (42 mmol/mol) and 10% (86 mmol/mol).
- Earlier treatment
- Diabetes managed with diet and exercise alone, or with a stable dose of an oral glucose-lowering medicine. Stable body weight (5% change or less) for at least 3 months. At least one self-reported unsuccessful attempt to lose weight. No GLP-1 medicine in the 3 months before randomisation. No insulin for type 2 diabetes in the 3 months before screening.
- Biomarker or test result
- HbA1c of 6.0% (42 mmol/mol) to 10% (86 mmol/mol) at screening.
Main reasons for not taking part
- Obesity mainly caused by another hormone disorder
- Type 1 diabetes or diabetes that is not clearly type 2
- Ketoacidosis or hyperosmolar coma/state in the 3 months before screening
- Significant liver or bile duct disease, or ALT or AST of 3.0 X ULN or more, or TBL above 1.5 X ULN
- GLP-1 medicine in the 3 months before randomisation
Read by machine on 12 November 2026.
Where in Argentina
- Buenos AiresHospital not named in the registryTaking people
- CABAHospital not named in the registryTaking people
- Ciudad de Buenos AiresHospital not named in the registryTaking people
- MendozaHospital not named in the registryTaking people
- Ramos MejíaHospital not named in the registryNot yet recruiting
- RosarioHospital not named in the registryTaking people
- San NicolásHospital not named in the registryNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07784270
- Record updated
- 28 October 2026
- Original description
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatmentRead full original descriptionShow less
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Inclusion: Males \& females (inclusive of all gender identities) age ≥18 years; BMI ≥27 kg/m2; Diagnosed with T2DM ≥90 days prior to Screening; HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling); Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation; History of at least one self-reported unsuccessful attempt to lose body weight in lifetime.
Exclusion: Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening; Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation; Use of insulin therapy for T2DM within 3 months prior to screening; Obesity primarily caused by other endocrine disorders; Significant hepatobiliary disease and/or any of the following results at Screening:; ALT ≥ 3.0 X ULN; AST ≥ 3.0 X ULN; TBL > 1.5 X ULN (except for cases of known Gilbert's Syndrome).